Latest Breaking News On - Resolution therapeutics - Page 1 : comparemela.com

Cellular Origins, a TTP Company, Establishes Advisory Board of Global Industry Leaders

Cellular Origins, a TTP Company, Establishes Advisory Board of Global Industry Leaders
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

John campbellPaul robertsMatthew liSarah jefferyGeoffrey hodgeNational head of researchScience group plcScottish national blood transfusion service in edinburghZyme communicationsGe healthcareProfessor john campbellAdvisory boardCellular originResolution therapeuticsAdvanced therapeuticsNational head

Cellular Origins, a TTP Company, establishes Advisory Board of global industry leaders

Renowned experts from across the CGT and robotics industries, Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge appointed to provide strategic and technical perspectives.

Geoffrey hodgePaul robertsJohn campbellMatthew liGe healthcareScience group plcNational head of researchScottish national blood transfusion service in edinburghCellular originsAdvisory boardProfessor john campbellCellular originResolution therapeuticsAdvanced therapeuticsNational headScottish national blood transfusion service

Cutting-edge therapy is the first treatment that could put liver damage from cirrhosis in reverse

The cutting-edge therapy is the first to treat cirrhosis, the scarring of liver tissue caused by heavy drinking, fatty diets and long-term infections from the viruses hepatitis B and C.

United kingdomUnited statesCity ofStuart forbesJonathan fallowfieldUniversity of edinburghAmerican associationLiver diseasesProfessor stuart forbesProfessor jonathan fallowfieldResolution therapeutics

From Pioneers to Innovators: Scotland s journey to conquer liver disease

Liver disease is a huge global health problem, affecting an estimated 1.5 billion people and resulting in over two million deaths yearly.

United kingdomPrakash ramachandranEdinburgh bioquarterDanielle ellisJonathan fallowfieldNanostring cosmxPublic health scotlandScottish national health serviceResearch squareUniversity of edinburgh centre for inflammation researchUniversity of edinburghPrecision medicine researchNational health serviceClinical fellowConsultant hepatologistKeynote contributor

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

These 2 randomized clinical trials compare the efficacy and safety of 2 doses of the autotaxin inhibitor ziritaxestat vs placebo in patients with idiopathic pul

Eteläuomen läiUnited statesLos angelesVicore pharmaDevpro biopharmaAstrazeneca daiichi sankyoRedx pharmaTobym maherShionogi co ltdCare center networkJanssen pharmaceuticalsKinevant sciencesBristol myers squibbPuretech healthGilead sciencesBoehringer ingelheim